⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ALT News

Altimmune, Inc. Common Stock

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity